according to the OSHA Hazard Communication Standard



Betamethasone / Clotrimazole Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
7.10	09/30/2023	610358-00019	Date of first issue: 04/08/2016

SECTION 1. IDENTIFICATION

Product name	:	Betamethasone / Clotrimazole Ointment Formulation			
Manufacturer or supplier's details					
Company name of supplier	:	Organon & Co.			
Address	:	30 Hudson Street, 33nd floor			
		Jersey City, New Jersey, U.S.A 07302			
Telephone	:	1-551-430-6000			
Emergency telephone	:	1-215-631-6999			
E-mail address	:	EHSSTEWARD@organon.com			
Recommended use of the chemical and restrictions on use					
Recommended use	:	Pharmaceutical			
Restrictions on use	:	Not applicable			

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)				
Reproductive toxicity	:	Category 1B		
Specific target organ toxicity - repeated exposure	:	Category 1 (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland)		
Specific target organ toxicity - repeated exposure (Oral)	:	Category 2 (Liver, Kidney, Adrenal gland)		
GHS label elements				
Hazard pictograms	:			
Signal Word	:	Danger		
Hazard Statements	:	 H360Df May damage the unborn child. Suspected of damaging fertility. H372 Causes damage to organs (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) through prolonged or repeated exposure. H373 May cause damage to organs (Liver, Kidney, Adrenal gland) through prolonged or repeated exposure if swallowed. 		
Precautionary Statements	:	Prevention: P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe dust, fume, gas, mist, vapors or spray.		

according to the OSHA Hazard Communication Standard



Betamethasone / Clotrimazole Ointment Formulation

sion 0	Revision Date: 09/30/2023	SDS Number: 610358-00019	Date of last issue: 04/04/2023 Date of first issue: 04/08/2016
		P270 Do not e	in thoroughly after handling. at, drink or smoke when using this product. otective gloves, protective clothing, eye protectior ction.
		Response: P308 + P313 I	F exposed or concerned: Get medical attention.
		Storage: P405 Store loc	sked up.
		Disposal: P501 Dispose disposal plant.	of contents and container to an approved waste
Othe	r hazards		
None	known.		

Substance / Mixture :	Mixture	
Components		
Chemical name	CAS-No.	Concentration (% w/w)
Petrolatum	8009-03-8	>= 90 - <= 100
White mineral oil (petroleum)	8042-47-5	>= 5 - < 10
clotrimazole	23593-75-1	>= 1 - < 5
Betamethasone	378-44-9	>= 0.01 - < 0.1

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and	:	



Betamethasone / Clotrimazole Ointment Formulation

Versior 7.10	Version Revision Date: SDS Number: 7.10 09/30/2023 610358-00019		Date of last issue: 04/04/2023 Date of first issue: 04/08/2016				
delayed			Causes damage to organs through prolonged or repeated				
Protection of first-aiders		:	 exposure. First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). 				
No	otes to physician	:		cally and supportively.			
SECTIO	ON 5. FIRE-FIGHTING ME	ASU	RES				
Suitable extinguishing media		:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical				
	nsuitable extinguishing edia	:	None known.				
	Specific hazards during fire fighting Hazardous combustion prod- ucts		: Exposure to combustion products may be a hazard to health				
Ha			Carbon oxides				
Specific extinguishing meth- ods		:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to so. Evacuate area.				
Special protective equipment for fire-fighters		:	In the event of fire	e, wear self-contained breathing apparatus. tective equipment.			
SECTIO	ON 6. ACCIDENTAL RELE	ASI	EMEASURES				
tiv	ersonal precautions, protec- e equipment and emer- ency procedures	:	Follow safe hand	tective equipment. ing advice (see section 7) and personal lent recommendations (see section 8).			
Er	vironmental precautions	:	Avoid release to t	he environment.			

		Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Sweep up or vacuum up spillage and collect in suitable container for disposal. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

according to the OSHA Hazard Communication Standard



Betamethasone / Clotrimazole Ointment Formulation

Version 7.10	Revision Date: 09/30/2023	SDS Number: 610358-00019	Date of last issue: 04/04/2023 Date of first issue: 04/08/2016		
Technical measures Local/Total ventilation Advice on safe handling		 CONTROLS// If sufficient vere ventilation. Do not get on Do not breath Do not swallo Avoid contact Wash skin the Handle in accord 	 See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section. If sufficient ventilation is unavailable, use with local exhaust ventilation. Do not get on skin or clothing. Do not breathe dust, fume, gas, mist, vapors or spray. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure 		
		assessment Keep contain Do not eat, dr	er tightly closed. ink or smoke when using this product. prevent spills, waste and minimize release to the		
Con	ditions for safe storage	Store locked Keep tightly c			
Materials to avoid		 Do not store with the following product types: Strong oxidizing agents Self-reactive substances and mixtures Organic peroxides Explosives Gases 			

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Petrolatum	8009-03-8	TWA (Inhal- able particu- late matter)	5 mg/m³	ACGIH
		TWA (Mist)	5 mg/m ³	OSHA Z-1
		TWA (Mist)	5 mg/m³	NIOSH REL
		ST (Mist)	10 mg/m ³	NIOSH REL
White mineral oil (petroleum)	8042-47-5	TWA (Inhal- able particu- late matter)	5 mg/m³	ACGIH
		TWA (Mist)	5 mg/m³	OSHA Z-1
		TWA (Mist)	5 mg/m³	NIOSH REL
		ST (Mist)	10 mg/m ³	NIOSH REL
clotrimazole	23593-75-1	TWA	0.2 mg/m3 (OEB 2)	Internal
Betamethasone	378-44-9	TWA	1 µg/m3 (OEB 4)	Internal
	Further information: Skin			
		Wipe limit	10 µg/100 cm ²	Internal

according to the OSHA Hazard Communication Standard



Versi 7.10	on Revision Date: 09/30/2023	SDS Number: 610358-00019	Date of last issue: 04/04/2023 Date of first issue: 04/08/2016
I	Engineering measures	are required to co the compound to from a closed sys stationary contain All engineering co design and opera protect products, Essentially no ope	anologies suitable for controlling compounds ontrol at source and to prevent migration of uncontrolled areas (e.g., vacuum conveying otem, packout head with inflatable seal from her, ventilated enclosure, etc.). ontrols should be implemented by facility ted in accordance with GMP principles to workers, and the environment. en handling permitted. sssing systems or containment technologies.
	Personal protective equipm		
I	Respiratory protection	maintain vapor ex concentrations ar unknown, approp Follow OSHA res use NIOSH/MSH by air purifying re hazardous chemi supplied respirato release, exposure	I exhaust ventilation is recommended to construct to the second
I	Hand protection	adequate protecti	01.
Material		: Chemical-resistar	nt gloves
I	Remarks Eye protection	If the work enviro mists or aerosols Wear a faceshield	gloving. ses with side shields or goggles. nment or activity involves dusty conditions, , wear the appropriate goggles. d or other full face protection if there is a t contact to the face with dusts, mists, or
č	Skin and body protection	: Work uniform or la Additional body g task being perforr disposable suits)	arments should be used based upon the med (e.g., sleevelets, apron, gauntlets, to avoid exposed skin surfaces. degowning techniques to remove potentially
ł	Hygiene measures	: If exposure to che eye flushing syste working place. When using do no Wash contaminat The effective ope engineering contr appropriate dego	emical is likely during typical use, provide ems and safety showers close to the ot eat, drink or smoke. red clothing before re-use. ration of a facility should include review of rols, proper personal protective equipment, wning and decontamination procedures, e monitoring, medical surveillance and the



Vers 7.10		Revision Date: 09/30/2023	SDS Number: 610358-00019		Date of last issue: 04/04/2023 Date of first issue: 04/08/2016
<u>850</u>		PHYSICAL AND CHE			3
SEC					
	Appeara	ance	÷	Viscous semi-sol	
	Color		:	No data available	9
	Odor		:	No data available	9
	Odor Th	nreshold	:	No data available)
	рН		:	No data available	9
	Melting	point/freezing point	:	No data available)
	Initial bo range	oiling point and boiling	:	No data available	
	Flash p	oint	:	Not applicable	
	Evapora	ation rate	:	Not applicable	
	Flamma	ability (solid, gas)	:	Not classified as	a flammability hazard
	Flamma	ability (liquids)	:	No data available	9
		explosion limit / Upper bility limit	:	No data available	2
		explosion limit / Lower bility limit	:	No data available	
	Vapor p	pressure	:	Not applicable	
	Relative	e vapor density	:	Not applicable	
	Relative	e density	:	No data available	9
	Density		:	No data available	9
	Solubilit Wate	ty(ies) er solubility	:	No data available	9
		n coefficient: n-	:	Not applicable	
	octanol/ Autoign	/water ition temperature	:	No data available	9
	Decom	position temperature	:	No data available	9
	Viscosit Visc	ty osity, kinematic	:	No data available	
	Explosi	ve properties	:	Not explosive	

according to the OSHA Hazard Communication Standard



Betamethasone / Clotrimazole Ointment Formulation

Version 7.10	Revision Date: 09/30/2023		S Number: 0358-00019	Date of last issue: 04/04/2023 Date of first issue: 04/08/2016
	zing properties cle size	:	The substance on Not applicable	or mixture is not classified as oxidizing.
Reac Chen Possi tions Cond Incon	nical stability ibility of hazardous reac- litions to avoid npatible materials rdous decomposition	::	Not classified as Stable under not Can react with s None known. Oxidizing agents	trong oxidizing agents.
Infor Skin (Inges	11. TOXICOLOGICAL I mation on likely routes contact stion contact			

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity :	Acute toxicity estimate: > 5,000 mg/kg Method: Calculation method
Acute dermal toxicity :	Acute toxicity estimate: > 5,000 mg/kg Method: Calculation method
Components:	
Petrolatum:	
Acute oral toxicity :	LD50 (Rat): > 5,000 mg/kg Method: OECD Test Guideline 401 Remarks: Based on data from similar materials
Acute dermal toxicity :	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 402 Assessment: The substance or mixture has no acute dermal toxicity Remarks: Based on data from similar materials
White mineral oil (petroleum):	
A outo oral taxiaity	$I D = 0$ (Dot): $\sim = 0.00$ mg/kg

according to the OSHA Hazard Communication Standard



rsion 0	Revision Date: 09/30/2023		0S Number: 0358-00019	Date of last issue: 04/04/2023 Date of first issue: 04/08/2016
Acute	inhalation toxicity	:	LC50 (Rat): > 5 Exposure time: Test atmospher Assessment: Th tion toxicity	4 h
Acute	dermal toxicity	:	LD50 (Rabbit): Assessment: Th toxicity	> 2,000 mg/kg ne substance or mixture has no acute dermal
clotrir	nazole:			
Acute	oral toxicity	:	LD50 (Rat): 708	3 mg/kg
			LD50 (Mouse):	761 mg/kg
			LD50 (Rabbit):	> 1,000 mg/kg
Acute	inhalation toxicity	:	LC50 (Rat): > 0 Exposure time: Test atmospher	4 h
Acute	dermal toxicity	:	LD50 (Mouse):	923 mg/kg
Betam	nethasone:			
Acute	oral toxicity	:	LD50 (Rat): > 5	,000 mg/kg
			LD50 (Mouse):	> 4,500 mg/kg
Acute	inhalation toxicity	:	LC50 (Rat): 0.4 Exposure time:	
	corrosion/irritation	ilahla	information	
	onents:	indolo		
Petrol	atum:			
Specie		:	Rabbit	
Metho Result		:	OECD Test Gui No skin irritatior	
Result				i irom similar materials
. conta		•		
	mineral oil (petrole	u m):	Dobb [:] *	
Specie Result		:	Rabbit No skin irritatior	1
	mazole:			
clotrir				

according to the OSHA Hazard Communication Standard



ersion .10	Revision Date: 09/30/2023	SDS Number: 610358-00019	Date of last issue: 04/04/2023 Date of first issue: 04/08/2016	
Resu	lt	: No skin irri	ation	
Betar	methasone:			
Speci	ies	: Rabbit		
Resu		: Mild skin ir	ritation	
	ous eye damage/eye			
Not c	lassified based on av	ailable information.		
Com	ponents:			
Petro	olatum:			
Speci	ies	: Rabbit		
Resu		: No eye irrit		
Metho			t Guideline 405	
Rema	arks	: Based on c	lata from similar materials	
White	e mineral oil (petrole	eum):		
Speci		: Rabbit		
Resu	lt	: No eye irrit	ation	
clotri	mazole:			
Speci	ies	: Rabbit		
Resu	lt	: Mild eye irr	itation	
Betar	methasone:			
Speci	ies	: Rabbit		
Resu		: No eye irrit	ation	
Resp	iratory or skin sens	itization		
Skin	sensitization			
Not c	lassified based on av	ailable information.		
Resp	iratory sensitization	1		
Not c	lassified based on av	ailable information.		
Com	ponents:			
	platum:			
Test		: Buehler Te		
	es of exposure	: Skin conta	ct	
Speci Resu		: Guinea pig		
Resu		: negative : Based on c	lata from similar materials	
1/GIIIC				
	e mineral oil (petrole			
Test	Туре	: Buehler Te	st	

according to the OSHA Hazard Communication Standard



Routes of exposureSkin contactSpeciesGuinea pigResultnegativeBetamethasone:Routes of exposureSpeciesCuinea pigSpeciesGuinea pigResultWeak sensitizerGern cell mutagenicityWeak sensitizerDetrolatum:Gernotoxicity in vitroGenotoxicity in vitroTest Type: Chromosome aberration test in vitro Result: negative Remarks: Based on data from similar materialsGenotoxicity in vitroTest Type: Mammalian erythrocyte micronucleus test (in vivo Cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negativeGenotoxicity in vivoTest Type: Mammalian erythrocyte micronucleus test (in vivo Cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negativeGenotoxicity in vitroTest Type: Mammalian erythrocyte micronucleus test (in vivo Cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Result: negativeGenotoxicity in vitroTest Type: Mammalian erythrocyte micronucleus test (in vivo Cytogenetic assay) Result: negativeGenotoxicity in vitroTest Type: Bacterial reverse mutation assay (AMES) Result: negativeClotrimazole:Test Type: Chromosome aberration test in vitro Result: negativeClotrimazole:Test Type: Chromosome aberration test in vitro Result: negativeGenotoxicity in vitroTest Type: Chromosome aberration test in vitro Result: negativeClotrimazole:Test Type: In vitro micronucleus test Result: negat	Version 7.10	Revision Date: 09/30/2023	SDS Number: 610358-00019	Date of last issue: 04/04/2023 Date of first issue: 04/08/2016
Routes of exposure : Dermal Species : Guinea pig Result : Weak sensitizer Gern cell mutagenicity Not classified based on available information. Components: Petrolatum: Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro Result: negative Remarks: Based on data from similar materials Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negative Genotoxicity in vivo : Test Type: In vitro mammalian cell gene mutation test Result: negative Result: negative Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Mute mineral oil (petroleum): : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection <tr< td=""><td>Spec</td><td>cies</td><td>: Guinea pig</td><td></td></tr<>	Spec	cies	: Guinea pig	
Species : Guinea pig Result : Weak sensitizer Gern cell mutagenicity Not classified based on available information. Components: Petrolatum: Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro Result: negative Remarks: Based on data from similar materials Genotoxicity in vitro : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materials White mineral oil (petroleum): Remarks: Based on data from similar materials Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test Result: negative Genotoxicity in vitro : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negative Result: negative Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materials	Beta	methasone:		
Not classified based on available information. Components: Petrolatum: Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro Result: negative Remarks: Based on data from similar materials Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negative Result: negative Remarks: Based on data from similar materials White mineral oil (petroleum): Genotoxicity in vitro : Test Type: In vitro mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse 	Spec	cies	: Guinea pig	er
Petrolatum: Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro Result: negative Remarks: Based on data from similar materials Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materials White mineral oil (petroleum): Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test Result: negative Genotoxicity in vitro : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negative Genotoxicity in vitro : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negative Genotoxicity in vivo : Test Type: Bacterial reverse mutation assay (AMES) Result: negative Clotrimazole: Est Type: Chromosome aberration test in vitro Result: negative Test Type: in vitro micronucleus test Test Type: in vitro micronucleus test Result: negative Test Type: in vitro micronucleus test			ailable information.	
Genotoxicity in vitro: Test Type: Chromosome aberration test in vitro Result: negative Remarks: Based on data from similar materialsGenotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materialsWhite mineral oil (petroleum): Genotoxicity in vitro: Test Type: In vitro mammalian cell gene mutation test Result: negativeGenotoxicity in vitro: Test Type: In vitro mammalian cell gene mutation test Result: negativeGenotoxicity in vitro: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negativeGenotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negative Result: negativeclotrimazole::Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES) Result: negativeclotrimazole::Genotoxicity in vitro: Test Type: Chromosome aberration test in vitro Result: negative:::::::::::::::::::::::::::::: <td>Com</td> <td><u>iponents:</u></td> <td></td> <td></td>	Com	<u>iponents:</u>		
Result: negative Remarks: Based on data from similar materials Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materials White mineral oil (petroleum): Genotoxicity in vitro Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test Result: negative Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materials clotrimazole: : Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES) Result: negative Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro Result: negative	Petr	olatum:		
cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materials White mineral oil (petroleum): Genotoxicity in vitro Enotoxicity in vitro Test Type: In vitro mammalian cell gene mutation test Result: negative Genotoxicity in vivo Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materials clotrimazole: Genotoxicity in vitro Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: Chromosome aberration test in vitro Result: negative Test Type: in vitro micronucleus test Result: negative Test Type: in vitro micronucleus test Result: negative	Gen	otoxicity in vitro	Result: negati	ve
Genotoxicity in vitro: Test Type: In vitro mammalian cell gene mutation test Result: negativeGenotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materialsclotrimazole: Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: Chromosome aberration test in vitro Result: negative Test Type: in vitro micronucleus test Result: negative	Gen	otoxicity in vivo	cytogenetic as Species: Mou Application Ro Method: OEC Result: negati	ssay) se oute: Intraperitoneal injection D Test Guideline 474 ive
Genotoxicity in vitro: Test Type: In vitro mammalian cell gene mutation test Result: negativeGenotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materialsclotrimazole: Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: Chromosome aberration test in vitro Result: negative Test Type: in vitro micronucleus test Result: negative	Whit	te mineral oil (petrole	um):	
cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materialsclotrimazole: Genotoxicity in vitro:Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: Chromosome aberration test in vitro Result: negativeTest Type: in vitro micronucleus test Result: negative	Gen	otoxicity in vitro		
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: Chromosome aberration test in vitro Result: negative Test Type: in vitro micronucleus test Result: negative	Gen	otoxicity in vivo	cytogenetic as Species: Mou Application Ro Method: OEC Result: negati	ssay) se oute: Intraperitoneal injection D Test Guideline 474 ve
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: Chromosome aberration test in vitro Result: negative Test Type: in vitro micronucleus test Result: negative	cloti	rimazole:		
Result: negative Test Type: in vitro micronucleus test Result: negative				
Result: negative				
Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo				
	Gen	otoxicity in vivo	: Test Type: Ma	ammalian erythrocyte micronucleus test (in vivo

according to the OSHA Hazard Communication Standard



Betamethasone / Clotrimazole Ointment Formulation

Versi 7.10	ion	Revision Date: 09/30/2023		OS Number: 0358-00019	Date of last issue: 04/04/2023 Date of first issue: 04/08/2016
				cytogenetic assay Species: Rat Application Route Result: negative	: Oral
				Test Type: Mamm tion test (in vivo) Species: Hamster Result: negative	nalian spermatogonial chromosome aberra-
	Germ c Assess	ell mutagenicity - ment	:	Weight of evidenc cell mutagen.	e does not support classification as a germ
	Betam	ethasone:			
	Genoto	xicity in vitro	:	Test Type: Bacter Result: negative	ial reverse mutation assay (AMES)
				Test Type: In vitro Result: negative	mammalian cell gene mutation test
				Test Type: Chrom Result: positive	nosome aberration test in vitro
	Genoto	xicity in vivo	:	Test Type: Mamm cytogenetic assay Species: Mouse Application Route Result: equivocal	
	Germ c Assess	ell mutagenicity - ment	:	Weight of evidenc	e does not support classification as a germ
	Carcin	ogenicity			

Carcinogenicity

Not classified based on available information.

Components:

Petrolatum:

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	2 Years
Result	:	negative

White mineral oil (petroleum):

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	24 Months
Result	:	negative

according to the OSHA Hazard Communication Standard



Version 7.10	Revision Date 09/30/2023	: SDS Number 610358-0001					
clotrii	mazole:						
	ation Route	: Rat : Oral : 78 weeks : negative					
IARC			of this product present at levels greater than or equal to 0.1% is obable, possible or confirmed human carcinogen by IARC.				
OSHA		mponent of this produc HA's list of regulated o	ct present at levels greater than or equal to 0.1% is carcinogens.				
NTP			present at levels greater than or equal to 0.1% is cipated carcinogen by NTP.				
-	oductive toxicity lamage the unbo	rn child. Suspected of	damaging fertility.				
Comp	onents:						
	latum:						
Effect	s on fertility	test Species: I Applicatio Result: ne	n Route: Ingestion				
Effects	Effects on fetal development		e: Embryo-fetal development Rat n Route: Skin contact egative Based on data from similar materials				
White	mineral oil (pe	troleum):					
	s on fertility	: Test Type Species: I	n Route: Skin contact				
Effect	s on fetal develo	Species: I	n Route: Ingestion				
clotri	mazole:						
	s on fertility	Species: I Applicatio	e: Fertility/early embryonic development Rat n Route: Oral OAEL: 50 mg/kg body weight				

according to the OSHA Hazard Communication Standard



Vers 7.10	-	Revision Date: 09/30/2023		9S Number: 0358-00019	Date of last issue: 04/04/2023 Date of first issue: 04/08/2016
				Result: Effects on	fertility.
	Effects on fetal development		:	Species: Rat Application Route Developmental To	ro-fetal development : Oral oxicity: LOAEL: 100 mg/kg body weight etal toxicity., No teratogenic effects.
				Species: Rat Application Route Developmental To	ro-fetal development : Oral oxicity: NOAEL: 50 mg/kg body weight etal toxicity., No teratogenic effects.
				Species: Mouse Application Route Developmental To	ro-fetal development : Oral oxicity: NOAEL: 200 mg/kg body weight o on fetal development.
				Species: Rabbit Application Route Developmental To	ro-fetal development : Oral oxicity: NOAEL: 180 mg/kg body weight o on fetal development.
	Reprod sessme	luctive toxicity - As- ent	:	fertility, based on	f adverse effects on sexual function and animal experiments., Some evidence of n development, based on animal
	Betam	ethasone:			
	Effects	on fetal development	:	•	: Intramuscular oxicity: LOAEL: 0.05 mg/kg body weight ty., Malformations were observed.
					: Subcutaneous oxicity: LOAEL: 0.42 mg/kg body weight ions were observed.
					: Intramuscular oxicity: LOAEL: 1 mg/kg body weight ions were observed.
	Reprod sessme	luctive toxicity - As- ent	:	Clear evidence of animal experimen	adverse effects on development, based on ts.



Betamethasone / Clotrimazole Ointment Formulation

Version 7.10	Revision Date: 09/30/2023		S Number: 0358-00019	Date of last issue: 04/04/2023 Date of first issue: 04/08/2016
	T-single exposure	-: - - -		
	lassified based on av		information.	
Caus renal May o	gland) through prolor	(Pituita	repeated expos	ne system, muscle, thymus gland, Blood, Ad- sure. enal gland) through prolonged or repeated ex-
Com	ponents:			
clotri	imazole:			
	et Organs ssment	:	Liver, Kidney, May cause dar exposure.	Adrenal gland mage to organs through prolonged or repeated
Beta	methasone:			
Targe	et Organs	:	Pituitary gland Adrenal gland	, Immune system, muscle, thymus gland, Blood
Asse	ssment	:	Causes damages damag	ge to organs through prolonged or repeated
Repe	eated dose toxicity			
<u>Com</u>	ponents:			
Petro	platum:			
Spec		:	Rat	
NOA		:	5,000 mg/kg	
	cation Route sure time	:	Ingestion 2 y	
White	e mineral oil (petrole	eum):		
Spec	ies	:	Rat	
LOAE		:	160 mg/kg	
	cation Route sure time	:	Ingestion 90 Days	
Spec		:	Rat	
LOAE		:	>= 1 mg/l	t/mict/fume)
	cation Route sure time		inhalation (dus 4 Weeks	winisviume)
Moth		:		udaliaa 110

: OECD Test Guideline 412

clotrimazole:

Method

Species	:	Rabbit
LÕAEL	:	5 - 40 mg/kg
Application Route	:	Skin contact
Exposure time	:	3 Weeks
Target Organs	:	Skin
l'arget Organs	•	OKIT

according to the OSHA Hazard Communication Standard



Version 7.10	Revision Date: 09/30/2023	SDS Number:Date of last issue: 04/04/2023610358-00019Date of first issue: 04/08/2016
Symp	toms	: Edema, Fissuring, Necrosis, Redness
Expos		: Rat : 10 mg/kg : Oral : 18 Months : Liver, Kidney, Adrenal gland
Expos	L cation Route sure time et Organs	 Dog 25 mg/kg Oral 6 - 12 Months Adrenal gland Salivation, Lachrymation, Vomiting
Speci LOAE Applic Expos		 Rabbit 0.05 % Skin contact 10 - 30 d Pituitary gland, Immune system, muscle
Expos		: Rat : 0.05 % : Skin contact : 8 Weeks : thymus gland
Expos		 Mouse 0.1 % Skin contact 8 Weeks thymus gland
Expos		: Dog : 0.05 mg/kg : Oral : 28 d : Blood, thymus gland, Adrenal gland
Not cl	ation toxicity lassified based on avail rience with human ex	
-	oonents:	
clotri Skin o Inges	mazole: contact	 Symptoms: Rash, Itching, Blistering, Edema, Redness Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhea
		45 / 00

according to the OSHA Hazard Communication Standard



Version 7.10	Revision Date: 09/30/2023		DS Number:Date of last issue: 04/04/20230358-00019Date of first issue: 04/08/2016
	nalation in contact	:	Target Organs: Adrenal gland Symptoms: Redness, pruritis, Irritation
SECTIC	ON 12. ECOLOGICAL INFO	DRN	ΜΑΤΙΟΝ
Ec	otoxicity		
<u>Co</u>	mponents:		
Pe	trolatum:		
To	xicity to fish	:	LL50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 203 Remarks: Based on data from similar materials
	xicity to daphnia and other uatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 10,000 mg/l Exposure time: 48 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials
	xicity to algae/aquatic ints	:	NOEL (Pseudokirchneriella subcapitata (green algae)): >= 100 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
aq	xicity to daphnia and other uatic invertebrates (Chron- oxicity)	:	NOEC (Daphnia magna (Water flea)): 10 mg/l Exposure time: 21 d Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials
Wł	nite mineral oil (petroleum	n):	
	xicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
	xicity to daphnia and other uatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
	xicity to algae/aquatic ints	:	NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
To: icit	xicity to fish (Chronic tox- y)	:	NOEC (Oncorhynchus mykiss (rainbow trout)): 1,000 mg/l Exposure time: 28 d
	xicity to daphnia and other uatic invertebrates (Chron-	:	NOEC (Daphnia magna (Water flea)): 1,000 mg/l Exposure time: 21 d

according to the OSHA Hazard Communication Standard



Vers 7.10		Revision Date: 09/30/2023		0S Number: 0358-00019	Date of last issue: 04/04/2023 Date of first issue: 04/08/2016		
	ic toxicity)						
	clotrim	azole:					
	Toxicity	/ to fish	:	 LC50 (Brachydanio rerio (zebrafish)): > 0.29 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 			
		/ to daphnia and other invertebrates	:	EC50 (Daphnia magna (Water flea)): 0.02 mg/l Exposure time: 48 h			
	Toxicity to algae/aquatic plants		:	EC50 (Desmodesmus subspicatus (green algae)): 0.268 mg/ Exposure time: 72 h			
				NOEC (Desmodes Exposure time: 72	smus subspicatus (green algae)): 0.017 mg/l ! h		
	Toxicity icity)	/ to fish (Chronic tox-	:	NOEC (Oncorhyn Exposure time: 32 Method: OECD Te			
		/ to daphnia and other invertebrates (Chron- ity)	:	NOEC (Daphnia n Exposure time: 21 Method: OECD Te			
	Toxicity	/ to microorganisms	:	: EC50: > 10,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209			
	Betam	ethasone:					
		/ to daphnia and other invertebrates	:	EC50 (Americamy Exposure time: 96			
	Toxicity plants	/ to algae/aquatic	:	mg/l Exposure time: 72 Method: OECD Te			
				mg/l Exposure time: 72 Method: OECD Te			
	Toxicity icity)	/ to fish (Chronic tox-	:	NOEC (Pimephale Exposure time: 32 Method: OECD Te			
				NOEC (Oryzias la Exposure time: 21 Method: OECD Te			



Betamethasone / Clotrimazole Ointment Formulation

Version 7.10	Revision Date: 09/30/2023		DS Number: 0358-00019	Date of last issue: 04/04/2023 Date of first issue: 04/08/2016
aqu	icity to daphnia and other atic invertebrates (Chron- oxicity)		Exposure time: 2	magna (Water flea)): 8 mg/l 1 d est Guideline 211
Per	sistence and degradabil	lity		
<u>Cor</u>	nponents:			
	rolatum: degradability	:		31 %
	ite mineral oil (petroleur degradability	n): :	Result: Not readil Biodegradation: Exposure time: 28	31 %
	trimazole: bility in water	:	Hydrolysis: 50 %((242 d)
Bio	accumulative potential			
<u>Cor</u>	nponents:			
Par	amethasone: tition coefficient: n- anol/water	:	log Pow: 2.11	
	bility in soil data available			
	e r adverse effects data available			
	N 13. DISPOSAL CONSI posal methods	DEF	RATIONS	

	Waste from residues	:	Dispose of in accordance with local regulations.
			Do not dispose of waste into sewer.
Contaminated packaging		:	Empty containers should be taken to an approved waste
			handling site for recycling or disposal.
			If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

according to the OSHA Hazard Communication Standard



Betamethasone / Clotrimazole Ointment Formulation

Version 7.10	Revision Date: 09/30/2023		S Number: 0358-00019	Date of last issue: 04/04/2023 Date of first issue: 04/08/2016
Prop	umber er shipping name	:	UN 3077 ENVIRONMENTA N.O.S. (betamethasone, 9 III	ALLY HAZARDOUS SUBSTANCE, SOLID, clotrimazole)
Labe		:	9 yes	
UN/II Prop Class	er shipping name s ing group	:	UN 3077 Environmentally h (Betamethasone, 9 III Miscellaneous	azardous substance, solid, n.o.s. , clotrimazole)
Pack aircra Pack ger a	ing instruction (cargo	:	956 956 yes	
UN n	3-Code umber er shipping name	:	UN 3077 ENVIRONMENTA N.O.S. (Betamethasone,	ALLY HAZARDOUS SUBSTANCE, SOLID,
Labe EmS	ing group	:	9 III 9 F-A, S-F yes	
	Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code Not applicable for product as supplied.		OL 73/78 and the IBC Code	
Dom	estic regulation			
Prop	D/NA number er shipping name	:	UN 3077 Environmentally h (Betamethasone,	nazardous substance, solid, n.o.s. , clotrimazole)
Labe ERG	ing group Is Code ne pollutant		liters.	ne, clotrimazole) ly to containers over 119 gallons or 450 nd under DOT is non-regulated; however it

Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.



Betamethasone / Clotrimazole Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
7.10	09/30/2023	610358-00019	Date of first issue: 04/08/2016

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards	:	Reproductive toxicity Specific target organ toxicity (single or repeated exposure)
SARA 313	:	This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know					
Petrolatum		8009-03-8			
White mineral oil (petro	oleum)	8042-47-5			
California List of Hazardous Su	ubstances				
Petrolatum		8009-03-8			
White mineral oil (petro	8042-47-5				
California Permissible Exposure Limits for Chemical Contaminants					
Petrolatum White mineral oil (petro	bleum)	8009-03-8 8042-47-5			
The ingredients of this product are reported in the following inventories:					
AICS :	not determined				
DSL :	not determined				
IECSC :	not determined				

SECTION 16. OTHER INFORMATION

Further information

according to the OSHA Hazard Communication Standard



Betamethasone / Clotrimazole Ointment Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04/04/2023 7.10 09/30/2023 610358-00019 Date of first issue: 04/08/2016 NFPA 704: HMIS® IV: Flammability * HEALTH 3 FLAMMABILITY 1 Health Instability 0 0 **PHYSICAL HAZARD** 0 HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents Special hazard a chronic hazard, while the "/" represents the absence of a chronic hazard. Full text of other abbreviations ACGIH USA. ACGIH Threshold Limit Values (TLV) NIOSH REL USA. NIOSH Recommended Exposure Limits OSHA Z-1 USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants ACGIH / TWA 8-hour, time-weighted average · Time-weighted average concentration for up to a 10-hour NIOSH REL / TWA workday during a 40-hour workweek NIOSH REL / ST STEL - 15-minute TWA exposure that should not be exceeded ÷ at any time during a workday

OSHA Z-1 / TWA : 8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable



Betamethasone / Clotrimazole Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
7.10	09/30/2023	610358-00019	Date of first issue: 04/08/2016

Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 09/30/2023

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8